Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.

Article Details

Citation
Copy to clipboard

Dillon JS, Chandrasekharan C

Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.

Future Oncol. 2018 May;14(12):1155-1164. doi: 10.2217/fon-2017-0340. Epub 2018 Jan 19.

PubMed ID
29350062 [ View in PubMed
]
Abstract

Carcinoid syndrome (CS), characterized by diarrhea and flushing, is present in 20% of patients with neuroendocrine tumors at diagnosis and becomes more frequent with progression. The diarrhea of CS is caused mainly by tumoral secretion of serotonin. It may not be fully controlled by somatostatin analogs, the currently indicated drugs for symptomatic relief. Telotristat ethyl is a novel inhibitor of tryptophan hydroxylase, the rate-limiting enzyme in serotonin biosynthesis. Administration of the drug decreases diarrhea in patients with CS. Telotristat ethyl was approved in February 2017 (USA) and September 2017 (European Commission) for the treatment of CS diarrhea in adults inadequately controlled by somatostatin analog alone. This drug is expected to greatly improve the health and quality of life of patients with CS diarrhea.

DrugBank Data that Cites this Article

Drugs